Abstract
Introduction: COVID-19 is the cause of a pandemic with high mortality rates that affect the entire world. In the present study, the importance of blood
parameters was investigated in predicting the severity of the disease in patients diagnosed with both covid19 and acute cholangitis simultaneously.
Methods: A total of 37 patient groups (n=37) who were diagnosed with both
COVID-19 and acute cholangitis, a total of 38 patients in the control group
(n=38) infected with Covid 19 and with no comorbidity, and 68 completely
healthy control group (n) =68) were included in the study retrospectively and
simultaneously. Those who had positive RT-PCR (Real-Time Polymerized
Chain Reaction) test results were included in the study. The results of routine biochemistry, serology, hormone, and blood gas tests of the patients were
compared with those of the control group. The Tokyo 2018 Criteria (TG18)
were used in the diagnosis of acute cholangitis and disease severity grading.
Results: The WBC(white blood cell), CRP(c-reactive protein), N/L Ratio(-
neutrophile/lynfosite ratio), AST(Aspartat Aminotransferaz), ALT(Alanin
Aminotransferaz), LDH(Laktate dehidrogenaz), GGT(Gama glutamil transferaz), ALP(alkalen fosfataz) total bilirubin, and direct bilirubin levels were
higher in the patient group at statistically significant levels than in the control
group (p<0.001). The albumin levels were lower than in the control group
(p<0.001). Total bilirubin/lymphocyte, GGT/lymphocyte, ALP/lymphocyte ratios, and D-dimer parameters had the highest AUC (Area Under the Curve) values in ROC analysis (0.984, 0.924, 0.923, and 0.897, respectively).
Conclusion: Total bilirubin/lymphocyte, GGT/lymphocyte, and ALP/lymphocyte ratios may be useful in predicting the severity of the disease
in acute cholangitis cases developing with COVID-19 simultaneously.
Details
| Primary Language | English |
|---|---|
| Subjects | Traditional, Complementary and Integrative Medicine (Other) |
| Journal Section | Research Articles |
| Authors | |
| Publication Date | March 28, 2023 |
| Published in Issue | Year 2023 |